Abatacept Uses
Links shared publicly online about this topic
Draft NICE Guidance Does Not Recommend Abatacept For Second-line Use In Rheumatoid Arthritis
medicalnewstoday.com — “The National Institute for Health and Clinical Excellence (NICE) has today (30 March 2011) opened a consultation on draft guidance which does not recommend abatacept (Orencia, Bristol-Myers Squibb” View full resource at medicalnewstoday.com
Most Recently Shared on March 31, 2011 at 2:56 am By:
Draft NICE Guidance Does Not Recommend Abatacept For Second-line Use In Rheumatoid Arthritis: The National Insti... http://bit.ly/dZu1fo
The use of abatacept in debilitating cavitating lung disease associated with rheumatoid arthritis, bronchocentric granulomatosis and aspergillosis -- Neff et al. 65 (6): 545 -- Thorax
thorax.bmj.com — “Neff, K; Stack, J; Harney, S; Henry, M” View full resource at thorax.bmj.com
Most Recently Shared on June 4, 2010 at 6:10 pm By:
The use of abatacept in debilitating cavitating lung disease associated with rheumatoid arthritis, bronchocentric ... http://bit.ly/9jT2NH
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
drugs.com — “Orencia (abatacept) is used for the treatment of rheumatoid arthritis. Information from Drugs.com includes Orencia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on August 2, 2011 at 12:14 am By:
Drugs and Devices OW OW Health
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-A... http://bit.ly/qnjY9u #drug
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
drugs.com — “Orencia (abatacept) is used for the treatment of rheumatoid arthritis. Information from Drugs.com includes Orencia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on August 2, 2011 at 12:27 am By:
FDA Approves Subcutaneous Formulation of Orencia - http://bit.ly/pjN8oc
New Hope for Immune Therapy for Children and Young Adults With Type 1 Diabetes: Founder of Orban Biotech's Landmark Findings for Abatacept Published in The Lancet
marketwire.com — “BROOKLINE, MA--(Marketwire - Aug 5, 2011) - Orban Biotech announced today that its C.E.O., Dr. Tihamer Orban, who was Principal Investigator for the Phase II clinical study run by TrialNet using Bristol Meyer's Abatacept for the treatment of Type 1 Diabetes Mellitus, presented the results of the trial at this...” View full resource at marketwire.com
Most Recently Shared on August 8, 2011 at 12:58 pm By:
Scott Strumello Patient Expert
New Hope for Immune Therapy for People With T1DM: Landmark Findings for Abatacept Published in The Lancet: http://t.co/9ciZoGb
European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis - Drugs.com MedNews
drugs.com — “European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment o” View full resource at drugs.com
Most Recently Shared on July 8, 2010 at 10:40 am By:
European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after... http://bit.ly/annWwg
Is It Ethical To Use Placebo In Rheumatoid Arthritis Clinical Trials? - QualityPoint Technologies
qualitypointtech.net — “The results of this study, conducted in Germany, re-open the debate on whether it is ethical to conduct placebo-controlled studies where patients in the placebo-group are at a serious disadvantage compared to patients taking the new treatments. The study analysed current study designs, for new therapies such as abatacept (Orencia®), golimumab (Simponi®) or tocilizumab (Actemra®), and showed that patients in the placebo group experienced no change in medication, having to continue with their form” View full resource at qualitypointtech.net
Most Recently Shared on May 30, 2011 at 8:45 am By:
Is It Ethical To Use Placebo In Rheumatoid Arthritis Clinical Trials?: The results of this study, conducted in Ger... http://bit.ly/jzp1Bh
New Data Show That Subcutaneous Injection Of An Investigational Formulation Of ORENCIA® Provided Similar Improvemnt Compared To Intraveous Therapy
medicalnewstoday.com — “(NYSE:BMY) announced that new Phase III clinical data show that a weekly subcutaneous injection of an investigational formulation of ORENCIA® (abatacept), following a single intravenous (I.V.)” View full resource at medicalnewstoday.com
Most Recently Shared on November 10, 2010 at 5:05 pm By:
MNT Arthritis News Health News
New Data Show That Subcutaneous Injection Of An Investigational Formulation Of ORENCIA® Provided Similar Improvemn... http://mnt.to/3Mm7
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
OrganizedWisdom RA
Organizing rheumatoid arthritis resources shared by health experts, advocates, and organizations into WisdomCards.
-
Lungs and Breathing
Organizing lung and breathing resources shared by health experts, advocates, and organizations into WisdomCards.
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
